Health Care & Life Sciences » Biotechnology | Regulus Therapeutics Inc.

Regulus Therapeutics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
19,569.00
7,669.00
20,759.00
1,194.00
72.00
72
SG&A Expense
36,011.00
51,089.00
73,926.00
80,420.00
67,679.00
43,773
EBIT
17,802.00
44,910.00
54,758.00
81,502.00
70,131.00
45,963
Unusual Expense
1,145.00
12,118.00
1,811.00
-
-
800
Interest Expense
36.00
39.00
52.00
1,182.00
2,723.00
2,343
Pretax Income
18,691.00
56,679.00
55,766.00
81,840.00
72,102.00
48,647
Income Tax
23.00
1.00
18.00
4.00
197.00
62
Consolidated Net Income
18,668.00
56,680.00
55,748.00
81,836.00
71,905.00
48,709
Net Income
18,668.00
56,680.00
55,748.00
81,836.00
71,905.00
48,709
Net Income After Extraordinaries
18,668.00
56,680.00
55,748.00
81,836.00
71,905.00
48,709
Net Income Available to Common
18,668.00
56,680.00
55,748.00
81,836.00
71,905.00
48,709
EPS (Basic)
0.49
1.29
1.08
1.55
0.96
5.59
Basic Shares Outstanding
38,479.40
44,090.20
51,411.40
52,813.50
75,230.80
8,718.60
EPS (Diluted)
0.49
1.29
1.08
1.55
0.96
5.59
Diluted Shares Outstanding
38,479.40
44,090.20
51,411.40
52,813.50
75,230.80
8,718.60
EBITDA
16,442.00
43,420.00
53,167.00
79,226.00
67,607.00
43,701
Non-Operating Interest Income
292.00
388.00
855.00
844.00
752.00
459

About Regulus Therapeutics

View Profile
Address
10628 Science Center Drive
San Diego California 92121
United States
Employees -
Website http://www.regulusrx.com
Updated 07/08/2019
Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.